a State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization , China Pharmaceutical University , Nanjing , People's Republic of China.
b Department of Medicinal Chemistry, School of Pharmacy , China Pharmaceutical University , Nanjing , People's Republic of China.
J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263. doi: 10.1080/14756366.2018.1480614.
With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine scaffold, showed good IDO1 inhibitory activity. To discover more compounds with similar structures to LVS-019, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivatives. Molecular docking studies suggested a possible binding mode of LVS-019, which provides a good starting point for the development of cyanopyridine scaffold compounds as potent IDO1 inhibitor. To improve potency of these hits, we further designed and synthesised another 14 derivatives of LVS-019. Among these compounds, LBJ-10 showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analogue. LBJ-10 can serve as ideal leads for further modifications as IDO1 inhibitors for cancer treatment.
为了发现新型 IDO1 抑制剂,采用了组合相似度搜索和分子对接方法,发现了 32 个命中化合物。对筛选出的命中化合物进行测试,得到了几种新型亚毫摩尔抑制剂。特别是具有氰基吡啶骨架的化合物 LVS-019,表现出良好的 IDO1 抑制活性。为了发现更多与 LVS-019 具有相似结构的化合物,基于它生成了一个基于形状的模型,并进行了第二轮虚拟筛选,得到了 23 个衍生物。分子对接研究表明了 LVS-019 的可能结合模式,为开发具有潜力的 IDO1 抑制剂的氰基吡啶骨架化合物提供了一个良好的起点。为了提高这些命中化合物的活性,我们进一步设计并合成了 LVS-019 的另外 14 个衍生物。在这些化合物中,LBJ-10 与命中化合物相比表现出了更高的活性,与对照 GDC-0919 类似物的活性相当。LBJ-10 可作为理想的先导化合物,进一步修饰为用于癌症治疗的 IDO1 抑制剂。